ASX Announcement
19 September 2025

Appendix 3Y - Change of Director's Interest Notice Lodgements

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") refers to the enclosed Appendix 3Y notices for Director interests in ordinary shares and options that were disposed on 23 December 2024 and 29 April 2025, Microba provides the following information in accordance with Listing Rule 3.19B:

1. Reason for late lodgement
The enclosed Appendix 3Y notices are being lodged outside the five business day timeframe required under Listing Rule 3.19A due to administrative oversight.

2. Current arrangements under Listing Rule 3.19B
Microba has arrangements in place with each of its Directors requiring them to promptly notify the Company Secretary of any changes in their notifiable interests in the company's securities. These arrangements are designed to support the company's compliance with its obligations under Listing Rule 3.19A.

3. Additional steps to ensure future compliance
To further support timely lodgement of future Appendix 3Y notices, MAP has:

- Incorporated director option expiry dates into its central compliance calendar
- Scheduled regular reviews of upcoming equity-related events by the Company Secretary.

Microba remains committed to meeting its continuous disclosure obligations in a timely manner.

This announcement has been authorised for release by the Company Secretary.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com

Investor / Media Relations
investor@microba.com
https://ir.microba.com/welcome

About Microba Life Sciences Limited
Microba Life Sciences is a company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Microba Life Sciences Ltd
ABN: 82 617 096 652

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Hyungtae Kim
Date of last notice	4 April 2022

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Indirect 2. Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1. Hyungtae Kim is a director nominee representing Macrogen, Inc. Macrogen, Inc. holds 17,828,431 Ordinary Shares
Date of change	29 April 2025
No. of securities held prior to change	1. 17,828,431 Ordinary Shares 2. 200,000 Options with an exercise price of $0.6632, expiring on 29 April 2025.
Class	Options
Number acquired	Nil
Number disposed	1. Nil 2. 200,000 Options with an exercise price of $0.6632, expiring on 29 April 2025.

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	1. 17,828,431 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of Options at expiry date.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Microba Life Sciences Ltd
ABN: 82 617 096 652

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Gene Tyson
Date of last notice	4 April 2022

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	a) Gene Tyson is a director and sole shareholder of Genie Microbiome Pty Ltd
Date of change	a) 23 December 2024 b) 29 April 2025
No. of securities held prior to change	1. 17,100,000 Ordinary Shares and 200,000 Options with an exercise price of $0.6632, expiring on 29 April 2025.
Class	Ordinary Shares & Options
Number acquired	Nil
Number disposed	a) 1,180,000 Ordinary Shares b) 200,000 Options with an exercise price of $0.6632, expiring on 29 April 2025.

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	a) Nil b) Nil
No. of securities held after change	1. 15,920,000 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	a) Transfer of Shares pursuant to a binding financial agreement following separation. b) Lapse of Options at expiry date.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.